FDA officials offer helping hand
This article was originally published in Clinica
In the widespread criticism of the FDA's Center for Devices & Radiological Health and the push for reform, one important fact seems to be overlooked: industry complaints centre on the process - not the headquarters personnel.
You may also be interested in...
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.